NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate of 4,525,976 shares of its common stock, no par value per share (or pre-funded warrants in lieu thereof) at an offering price of $5.75 per share in a registered direct offering. The purchase price per pre-funded warrant is identical to the purchase price per share of common stock, less the exercise price of $0.0001 per share. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions.

Lake Street Capital Markets, LLC is acting as the sole placement agent for the offering.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $26.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, including but not limited to research and development in the transplantation category.

Proceeds from the offering will allow the company to invest in research and development with the goal of expanding its GraftAssure product offering beyond kidney transplant rejection testing into other organs, and most immediately, into heart transplant rejection testing.

Bio-Rad Laboratories, Inc., a significant shareholder of iMDx, participated in the offering on the same terms as the other investors in the offering.

The securities described above are being offered and sold by the Company in a registered direct ...